AstraZeneca shareholders signal concerns over pay
Almost 40% of AstraZeneca shareholders deliver a blow to the pharmaceuticals company, by voting against its annual remuneration report.
Photo: Shutterstock
Pharmaceuticals giant AstraZeneca received a warning shot from shareholders when almost 40% voted against the company's annual remuneration report.
The vote at yesterday's annual general meeting saw 38.83% of shareholders oppose the report. The Times reported that it was the largest shareholder rebellion since Pascal Soriot became chief executive in 2012.
Soriot's pay rose by 70% last year, to £13.4m.
However, 96% of shareholders backed the company's new remuneration policy yesterday, indicating satisfaction with AstraZeneca's current approach.
A statement from the company after the meeting said: "AstraZeneca engaged extensivel
For thoughtful journalism, expert insights on corporate governance and an extensive library of reports, guides and tools to help boards and directors navigate the complexities of their roles, subscribe to Board Agenda
Related Stories
-
LGIM names companies performing badly on climate change
Investment manager Legal & General Investment Management increases pressure on companies over climate change by naming those it has disinvested from.
-
High Pay Commission declares ‘Fat Cat Wednesday’
Think-tank declares 4 January the day on which the average top boss has earned as much as the average worker will all year.
-
The UK has gone from leader to laggard on business and human rights
As new laws emerge around Europe, it’s time for the UK to hold business liable for human rights abuses in supply chains around the world.
